A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment

A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment

© 2025 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 37(2025), 42 vom: 30. Okt., Seite e04987
1. Verfasser: Zhang, Qiang (VerfasserIn)
Weitere Verfasser: Miao, Yu, Chen, Zhike, Liu, Yi, Chen, Linfu, Xiao, Zhisheng, Shen, Hui, Shen, Jingjing, Pan, Feng, Liu, Nanhui, Lv, Xinying, Zhao, Haibin, Yu, Qifan, Zheng, Zixuan, Chen, Qian, Yang, Yang
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2025
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article lung cancer natural polysaccharide noninvasive nanovaccine phenylboronic acid Cancer Vaccines Dextrans Polysaccharides Boronic Acids Nanovaccines
Beschreibung
Zusammenfassung:© 2025 Wiley‐VCH GmbH.
Lung cancer is the most widespread malignancy globally and the leading cause of cancer-related deaths, highlighting the need for innovative treatments. Herein, a novel inhaled vaccine carrier is presented by modifying dextran (Dex) with N,N-dimethylethylenediamine (DMEN) and 4-(bromomethyl)phenylboronic acid (PBA) (Dex-DMEN-PBA, DDP). The optimized DDP demonstrates a potent adjuvant effect in promoting dendritic cell (DC) maturation by multiple signaling pathways. Moreover, the nanovaccine (DDP/Lewis lung carcinoma (LLC)) forms through electrostatic interactions between DDP and protein antigens derived from LLC cells. Upon inhalation, it induces DC maturation, T cell activation, and germinal center B cell activation in the thoracic lymph node. In the mouse model, the inhaled DDP/LLC nanovaccine displays impressive prophylactic effects against lung cancer, with 50% of mice alive after six months and 33% surviving a subsequent challenge, indicating strong long-term immune memory. Remarkably, it surpasses subcutaneous vaccination, particularly in activating germinal center B cells and follicular helper T (Tfh) cells, and upregulating tissue-resident memory T (TRM) cells in the lung. This self-adjuvant nanovaccine effectively prevents tumor growth and induces robust immune memory, offering valuable insight for treating lung cancer and related diseases
Beschreibung:Date Completed 23.10.2025
Date Revised 23.10.2025
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202504987